Section 6 of 6
References
277 sources
- AbbVie HUMIRA prescribing information (2025) (opens in a new tab)
- AbbVie SKYRIZI prescribing information (2026) (opens in a new tab)
- Abuabara et al. (2010) (opens in a new tab)
- Al Sawah et al. (2017) (opens in a new tab)
- Alinaghi et al. (2019) (opens in a new tab)
- Alumis and Kaken press release, collaboration and licensing agreement (2025) (opens in a new tab)
- Alumis corporate presentation, November 2026 (2026) (opens in a new tab)
- Alumis envudeucitinib for psoriasis page (opens in a new tab)
- Alumis expanded access policy page (opens in a new tab)
- Alumis Form 10-K (2026) (opens in a new tab)
- Alumis Form 10-Q, second quarter 2026 (2026) (opens in a new tab)
- Alumis Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
- Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026) (opens in a new tab)
- Alumis press release, AAD 2025 OLE data (2025) (opens in a new tab)
- Alumis press release, AAD 2026 ONWARD data (2026) (opens in a new tab)
- Alumis press release, Fall Clinical 2026 ONWARD data (2026) (opens in a new tab)
- Alumis press release, first quarter 2025 results (2025) (opens in a new tab)
- Alumis press release, first quarter 2026 results (2026) (opens in a new tab)
- Alumis press release, LUMUS topline results (2026) (opens in a new tab)
- Alumis press release, ONWARD1 and ONWARD2 topline results (2026) (opens in a new tab)
- Alumis press release, ONWARD3 topline results (2026) (opens in a new tab)
- Alumis press release, second quarter 2025 results (2025) (opens in a new tab)
- Alumis press release, second quarter 2026 results (2026) (opens in a new tab)
- Alumis press release, third quarter 2024 results (2024) (opens in a new tab)
- Alumis press release, third quarter 2025 results (2025) (opens in a new tab)
- Alumis press release, third quarter 2026 results (2026) (opens in a new tab)
- Alumis press release, year end 2024 results (2025) (opens in a new tab)
- Alumis press release, year end 2025 results (2026) (opens in a new tab)
- Alumis STRIDE protocol (2022) (opens in a new tab)
- Alumis STRIDE statistical analysis plan (2023) (opens in a new tab)
- Amgen ENBREL prescribing information (2026) (opens in a new tab)
- Amgen OTEZLA prescribing information (2025) (opens in a new tab)
- Andrzejczak et al. (2026) (opens in a new tab)
- ANZCTR ACTRN12621000011886 (opens in a new tab)
- Armstrong and Read (2020b) (opens in a new tab)
- Armstrong et al. (2012) (opens in a new tab)
- Armstrong et al. (2013a) (opens in a new tab)
- Armstrong et al. (2013b) (opens in a new tab)
- Armstrong et al. (2013c) (opens in a new tab)
- Armstrong et al. (2013d) (opens in a new tab)
- Armstrong et al. (2017a) (opens in a new tab)
- Armstrong et al. (2017b) (opens in a new tab)
- Armstrong et al. (2017c) (opens in a new tab)
- Armstrong et al. (2018) (opens in a new tab)
- Armstrong et al. (2019) (opens in a new tab)
- Armstrong et al. (2020a) (opens in a new tab)
- Armstrong et al. (2021) (opens in a new tab)
- Armstrong et al. (2023a) (opens in a new tab)
- Armstrong et al. (2023b) (opens in a new tab)
- Armstrong et al. (2023c) (opens in a new tab)
- Armstrong et al. (2024) (opens in a new tab)
- Armstrong et al. (2025a) (opens in a new tab)
- Armstrong et al. (2025b) (opens in a new tab)
- Armstrong et al. (2025c) (opens in a new tab)
- Armstrong et al. (2026a) (opens in a new tab)
- Armstrong et al. (2026b) (opens in a new tab)
- Armstrong et al. (2026c) (opens in a new tab)
- Augustin et al. (2010) (opens in a new tab)
- Augustin et al. (2024) (opens in a new tab)
- Basra et al. (2007) (opens in a new tab)
- Bausch Health SILIQ prescribing information (2026) (opens in a new tab)
- Bellinato et al. (2022) (opens in a new tab)
- Bissonnette et al. (2018) (opens in a new tab)
- Bissonnette et al. (2025) (opens in a new tab)
- Blauvelt et al. (2021) (opens in a new tab)
- Blauvelt et al. (2024a) (opens in a new tab)
- Blauvelt et al. (2024b) (opens in a new tab)
- Blauvelt et al. (2025a) (opens in a new tab)
- Blauvelt et al. (2025b) (opens in a new tab)
- Blauvelt et al. (2026a) (opens in a new tab)
- Blauvelt et al. (2026b) (opens in a new tab)
- Blauvelt et al. (2026c) (opens in a new tab)
- Blauvelt et al. (2026d) (opens in a new tab)
- Bowles et al. (2025) (opens in a new tab)
- Bożek and Reich (2017) (opens in a new tab)
- Brezinski et al. (2015) (opens in a new tab)
- Bristol Myers Squibb press release, BMS Patient Connect platform (2025) (opens in a new tab)
- Bristol Myers Squibb SOTYKTU prescribing information (2026) (opens in a new tab)
- Budu-Aggrey et al. (2019) (opens in a new tab)
- Burshtein and Schlesinger (2026) (opens in a new tab)
- Burshtein et al. (2021) (opens in a new tab)
- California HCAI new prescription drugs introduced to market, January to October 2026 (2026) (opens in a new tab)
- California HCAI prescription drug WAC increases, January to October 2026 (2026) (opens in a new tab)
- Carlisle et al. (2020) (opens in a new tab)
- Carrico et al. (2020) (opens in a new tab)
- Chat et al. (2024) (opens in a new tab)
- Chen et al. (2025) (opens in a new tab)
- ClinicalTrials.gov NCT05330858 (opens in a new tab)
- ClinicalTrials.gov NCT05330858 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT05431634 (opens in a new tab)
- ClinicalTrials.gov NCT05431634 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT05600036 (opens in a new tab)
- ClinicalTrials.gov NCT05600036 results (opens in a new tab)
- ClinicalTrials.gov NCT05600036 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT05739435 (opens in a new tab)
- ClinicalTrials.gov NCT05739435 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT06586112 (opens in a new tab)
- ClinicalTrials.gov NCT06586112 API record (opens in a new tab)
- ClinicalTrials.gov NCT06586112 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT06588738 (opens in a new tab)
- ClinicalTrials.gov NCT06588738 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT06846541 (opens in a new tab)
- ClinicalTrials.gov NCT06952634 (opens in a new tab)
- ClinicalTrials.gov NCT06952634 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT06962774 (opens in a new tab)
- ClinicalTrials.gov NCT06962774 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT07378579 (opens in a new tab)
- CMS 2026 QCDR measure specifications (2026) (opens in a new tab)
- CMS fact sheet, third cycle of negotiation (2026) (opens in a new tab)
- CMS Medicare Part B payment limit file (2026) (opens in a new tab)
- CMS MIPS Quality ID 410 specification (2026) (opens in a new tab)
- CMS MIPS Quality ID 485 specification (2026) (opens in a new tab)
- CMS negotiated prices fact sheet (2025) (opens in a new tab)
- De Luca et al. (2026) (opens in a new tab)
- Dendrou et al. (2016) (opens in a new tab)
- Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026) (opens in a new tab)
- Dhana et al. (2019) (opens in a new tab)
- Dowlatshahi et al. (2014) (opens in a new tab)
- Eder et al. (2016) (opens in a new tab)
- Eghlileb et al. (2007) (opens in a new tab)
- Egilman et al. (2024) (opens in a new tab)
- Ehst et al. (2026) (opens in a new tab)
- Eli Lilly TALTZ prescribing information (2024) (opens in a new tab)
- Elmets et al. (2019a) (opens in a new tab)
- Elmets et al. (2019b) (opens in a new tab)
- Elmets et al. (2021) (opens in a new tab)
- EMA psoriasis clinical investigation guideline (2004) (opens in a new tab)
- EU Clinical Trials Register 2022-002633-34 (opens in a new tab)
- FDA UNII record for envudeucitinib (opens in a new tab)
- Feldman et al. (2015) (opens in a new tab)
- Feldman et al. (2016) (opens in a new tab)
- Feldman et al. (2018a) (opens in a new tab)
- Feldman et al. (2018b) (opens in a new tab)
- Feldman et al. (2019) (opens in a new tab)
- Fredriksson and Pettersson (1978) (opens in a new tab)
- Fu et al. (2018) (opens in a new tab)
- GBD 2019 IMID Collaborators (2023) (opens in a new tab)
- Gelfand et al. (2006) (opens in a new tab)
- Gelfand et al. (2007) (opens in a new tab)
- Gooderham et al. (2025) (opens in a new tab)
- Griffiths et al. (2021) (opens in a new tab)
- Grossschaedl et al. (2024) (opens in a new tab)
- Gu et al. (2025) (opens in a new tab)
- Guo et al. (2024) (opens in a new tab)
- Hagino et al. (2025) (opens in a new tab)
- Hawkes et al. (2017) (opens in a new tab)
- Hawkes et al. (2019) (opens in a new tab)
- Hawkes et al. (2026) (opens in a new tab)
- Hawro et al. (2015) (opens in a new tab)
- Health Research Authority research summary, ESK-001 metformin and paroxetine study (2025) (opens in a new tab)
- Helmick et al. (2014) (opens in a new tab)
- Hendrix et al. (2018) (opens in a new tab)
- Hongbo et al. (2005) (opens in a new tab)
- Icen et al. (2009) (opens in a new tab)
- ICER targeted immunomodulators for plaque psoriasis final evidence report (2016) (opens in a new tab)
- ICER targeted immunomodulators for plaque psoriasis final evidence report (2018) (opens in a new tab)
- ICH E1 population exposure guideline (1995) (opens in a new tab)
- Imafuku et al. (2023) (opens in a new tab)
- Ishihara et al. (2026) (opens in a new tab)
- Jalenques et al. (2022) (opens in a new tab)
- Janssen ICOTYDE prescribing information (2026) (opens in a new tab)
- Janssen REMICADE prescribing information (2025) (opens in a new tab)
- Janssen STELARA prescribing information (2026) (opens in a new tab)
- Janssen TREMFYA prescribing information (2026) (opens in a new tab)
- Jaworecka et al. (2021) (opens in a new tab)
- Jensen et al. (2023) (opens in a new tab)
- Jia et al. (2022) (opens in a new tab)
- Karpoff et al. (2026) (opens in a new tab)
- Kim et al. (2025) (opens in a new tab)
- Kong and Buzney (2026) (opens in a new tab)
- Korman et al. (2016) (opens in a new tab)
- Krueger et al. (2022) (opens in a new tab)
- Kumar et al. (2026) (opens in a new tab)
- Kurd and Gelfand (2009) (opens in a new tab)
- Kurd et al. (2010) (opens in a new tab)
- Langley et al. (2015) (opens in a new tab)
- Lebwohl et al. (2014) (opens in a new tab)
- Lebwohl et al. (2022) (opens in a new tab)
- Lebwohl et al. (2026a) (opens in a new tab)
- Lebwohl et al. (2026b) (opens in a new tab)
- Lønnberg et al. (2013) (opens in a new tab)
- Lovell et al. (2025) (opens in a new tab)
- Magnolo et al. (2026) (opens in a new tab)
- Marquez-Grap et al. (2025) (opens in a new tab)
- Martínez-García et al. (2014) (opens in a new tab)
- McCoy et al. (2023) (opens in a new tab)
- Mehrotra et al. (2026) (opens in a new tab)
- Mehta et al. (2010) (opens in a new tab)
- Menter et al. (2019) (opens in a new tab)
- Menter et al. (2020) (opens in a new tab)
- Merola et al. (2021) (opens in a new tab)
- Motedayen Aval et al. (2025) (opens in a new tab)
- Mrowietz et al. (2025) (opens in a new tab)
- Murage et al. (2018) (opens in a new tab)
- Narayan et al. (2025) (opens in a new tab)
- Narayan et al. (2026a) (opens in a new tab)
- Narayan et al. (2026b) (opens in a new tab)
- Nast et al. (2026a) (opens in a new tab)
- Nast et al. (2026b) (opens in a new tab)
- National Psoriasis Foundation position statement on psoriasis severity (2025) (opens in a new tab)
- National Psoriasis Foundation, FDA drops TB testing for Skyrizi (2026) (opens in a new tab)
- National Psoriasis Foundation, TB testing for new oral treatment (2026) (opens in a new tab)
- Noh et al. (2025) (opens in a new tab)
- Noot et al. (2026) (opens in a new tab)
- Novartis COSENTYX prescribing information (2026) (opens in a new tab)
- Novartis NEORAL prescribing information (2023) (opens in a new tab)
- Papp et al. (2015) (opens in a new tab)
- Papp et al. (2021) (opens in a new tab)
- Papp et al. (2024) (opens in a new tab)
- Papp et al. (2025a) (opens in a new tab)
- Papp et al. (2025b) (opens in a new tab)
- Papp et al. (2025c) (opens in a new tab)
- Papp et al. (2026) (opens in a new tab)
- Parisi et al. (2020) (opens in a new tab)
- Park et al. (2024) (opens in a new tab)
- Pasumarthi et al. (2026) (opens in a new tab)
- Patel et al. (2026) (opens in a new tab)
- Paul et al. (2015) (opens in a new tab)
- Pelet Del Toro et al. (2023) (opens in a new tab)
- Perlmutter et al. (2026) (opens in a new tab)
- Pilon et al. (2019) (opens in a new tab)
- Piragine et al. (2022) (opens in a new tab)
- Popatia et al. (2019) (opens in a new tab)
- Raharja et al. (2021) (opens in a new tab)
- Reich et al. (2021) (opens in a new tab)
- Rome et al. (2025) (opens in a new tab)
- Ryan et al. (2015) (opens in a new tab)
- Sbidian et al. (2025) (opens in a new tab)
- Schaefer et al. (2015) (opens in a new tab)
- Schneiderman and Derrick (2026) (opens in a new tab)
- Semenov et al. (2021) (opens in a new tab)
- Shah et al. (2024) (opens in a new tab)
- Shorla Oncology JYLAMVO prescribing information (2026) (opens in a new tab)
- Smith et al. (2024a) (opens in a new tab)
- Smith et al. (2024b) (opens in a new tab)
- Smith et al. (2025) (opens in a new tab)
- Snyder et al. (2023) (opens in a new tab)
- Spuls et al. (2010) (opens in a new tab)
- Stein Gold et al. (2025) (opens in a new tab)
- Stein Gold et al. (2026a) (opens in a new tab)
- Stein Gold et al. (2026b) (opens in a new tab)
- Stiefel SORIATANE prescribing information (2023) (opens in a new tab)
- Strober et al. (2019) (opens in a new tab)
- Strober et al. (2020) (opens in a new tab)
- Strober et al. (2023) (opens in a new tab)
- Strober et al. (2025) (opens in a new tab)
- Stuart et al. (2022) (opens in a new tab)
- Sun Pharma ILUMYA prescribing information (2026) (opens in a new tab)
- Takeda press release, LATITUDE Atlas results (2026) (opens in a new tab)
- Takeda press release, zasocitinib NDA acceptance (2026) (opens in a new tab)
- Takeda press release, zasocitinib skin clearance across body sites (2026) (opens in a new tab)
- Takeshita et al. (2015) (opens in a new tab)
- Teeple and Fitzgerald (2022) (opens in a new tab)
- Teeple and Muser (2019) (opens in a new tab)
- Texas DSHS 2026 annual WAC report (2026) (opens in a new tab)
- Tilley et al. (2024) (opens in a new tab)
- Tilley et al. (2026) (opens in a new tab)
- Tsai et al. (2024) (opens in a new tab)
- UCB BIMZELX prescribing information (2024) (opens in a new tab)
- UCB CIMZIA prescribing information (2025) (opens in a new tab)
- Ucpinar et al. (2024a) (opens in a new tab)
- Ucpinar et al. (2024b) (opens in a new tab)
- Ucpinar et al. (2024c) (opens in a new tab)
- Vanderpuye-Orgle et al. (2015) (opens in a new tab)
- Vazquez et al. (2023) (opens in a new tab)
- Villacorta et al. (2020) (opens in a new tab)
- Wan et al. (2020) (opens in a new tab)
- World Health Organization INN stem book (2024) (opens in a new tab)
- World Health Organization proposed INN list 130 (2023) (opens in a new tab)
- Wu et al. (2018) (opens in a new tab)
- Wu et al. (2021) (opens in a new tab)
- Wu et al. (2023) (opens in a new tab)
- Xu et al. (2023) (opens in a new tab)
- Yang et al. (2022) (opens in a new tab)
- Zhao et al. (2019) (opens in a new tab)
- Zheng et al. (2024) (opens in a new tab)
- Zhou et al. (2025) (opens in a new tab)